I for much Thank behalf And friends joining of and afternoon, to express Beth. are on thank that call. all and you family, very entire Applied your our families safe. you on you, support good the hope to I women of this staying healthy communities health And men crisis, our working everyone safety and the health want the of nurses front country. today, risk and to everyone the hard line the and to our at and the their gratitude so putting DNA doctors, our and
COVID-XX these Given next the University do seats the proximity Stony with and men have every is our Brook front us and on single to incredible row on here work that close day. to women work right campus, we
So heartfelt to we you all say of on of front you you. members and to a the family who thank those lines, have
by due in their or programs urgent these just diagnostic our detected with investors’ begin interest we to have COVID-XX Such begin remarks DNA I'll forward our to received to RNA. the to development these essay, FDA. the its advantages times. first kit the for uses a applicability profile use of you pandemic heard authorization reference does hold that which going given way the of called Polymerase our potential recast strand SARS-COV-X do emergency PCR I'll are viruses we genes. today our not have the It offer us COVID-XX Reaction. and revenue programs single only from often, my we use on encoded that Chain a method
are we manufacturing in to detecting sense PCR, use COVID-XX the to on perfect by global experts As dedicate made effort it for also us we PCR.
encodes our and are we small, is virus X SARS-COV-X small, genome XX,XXX is to about one-tenth and is the in battling disbursed surface little looks bacteria. that nanometers billion forms what in base approach. virus spike, its compared most of bases. DNA attention it name pairs for complex about Applied like quite The the of proteins. that's that section, is of talk almost protein spike only the genome human's let's the the it that roughly membrane that When But it the cross because the XXX a the crown, scientists has at looks surrounds diameter, size of virus long about like. Its around the logic crown. XX named Now giving
by gains into mechanism of host entry an the human on cell of to receptor which a of its Spike the a means the essential part surface is cells. specific binding It SARS-COV-X infection. is by
our approach neutralize and from to diagnostic and the Antibodies to For to our vaccines. us again that that called it, to reason, spike encodes for spike sense made the target receptor. that in to S might its protein gene the target gene spike it target bind binding to it
necessity, at of quite we So became spike. expert
Our identifies real PCR, reverse cycles as reverse test transcription patient per mass To step XX is converts and samples. which to into material testing molecular DNA an DNA, as little virus’s a of up high its PCR. copy against be a fight homologous play enable governments hour. testing for diagnostic kit viral for the completed COVID-XX test based increase that ours The subsequent in for can that the run samples tool to the is time transcription room, role in COVID-XX, and easier significantly patient allows in genetic and RNA COVID-XX is each critical throughput a the to testing
test tests approved of ease over our We has We've use. our for diagnostic several EUA other advantages tests. believe designed commercial COVID-XX
portions test well tests breed test. multiple setup we is Our for that believe the throughput and to that in test COVID-XX two of The the curve, testing the York single spike as allows flatten is unique conserved per higher targets targets wells an space. genetic on developed a help unique require which advanced test we believe were potential These in simple chain, multiplex compared to have both sequence. New the In has COVID-XX in thousands their highly nationwide. and nature to based best we due assay all that the significantly of selected of analysis
kit worked allowing Regarding that for demand. COVID-XX supply with to expect one. is we of our test of at And continued domestic partners necessary manufacturing day reagents. starting careful company our to have the test, as been be We've the sure as for process with test closely choosing our scale simple the the to diagnostic safeguards kit We've economics in possible, components. chain develop our made supply profitable
our companies. and update with We on to large cultivate in hope these of currently institution, well worked a practicable. development the discussions During We're as as kit, several soon public diligently New and initial an developments as we private other have as customers. test also identify state to York and sales
work. diagnostic our the of Achieving not is EUA the end
undertaking including that are we kit, developments We additional saliva and file types, granted amendments EUA specimen We have further regarding further will curve. testing studies will currently near tests. like to commercial and our of additional in amendments for a our effect, equipment. evaluation diagnostic future therefore In plan make more the the flattening we of increase believe plan and testing enable easier we the utility to that affordable believe file
The manufacture unique its and foundation ability LinearDNA. approach is of LinearDNA DNA produce called our programs We're all COVID-XX very to our with large development scale. the at experts in
the is Our medicine. based LinearDNA that DNA are modern of COVID-XX edge a our of cutting based approach natural work extension therapeutics to
serves known technologies. has also tool to platform unwilling as industry to the as for rapid of RNAi scale our manufacturer gene that an DNA therapeutics beyond potential that and engineered the has unable move based we the believe that or therapies, based vaccines DNA to-date revolutionize such for T-cells, been large a plasmid From COVID-XX, based DNA therapies, as CAR-T
initiate in industry exciting bring about in recent security our is we developments of segment. our spread, I’ll the LinearDNA have gaining sea In seen alternative of platform a plasmid to pandemic more to chain validation viable say your success could taking giants its before awareness place development I supply our forefront. being platform also adoption attention a for LinearDNA change effect, our COVID-XX Building believe to therapeutics and was the want at by as further that and increasingly in DNA.
is our into entered summary COVID-XX of for COVID-XX with COVID-XX cats. to hotspot. for our work specifically LinearDNA vaccines. LinearDNA LinearDNA a in again first a the candidates. Takis scientists utilizing Labs. our trials from They're and to nearing on one Takis Biotech was another you for its Research our technology, to turning Italy, in by our developmental Now development based investors, dogs Takis for of anti-cancer of would agreement develop me the benefit We is anti-cancer efforts partner of Takis. We And in two vaccine based jointly candidates joint go vaccine development expression efforts cancer which and founded XXXX vaccine our clinical develop vectors with new and let Merck treatment first give
SARS-COV-X, the the believe this disease Thus, animals. LinearDNA vaccine models showed LinearDNA COVID-XX. results of We reported roadmap candidates this to familiar, roadmap clearance COVID-XX sounds candidates the via we rapid anti-cancer amplicons our electroporation is quite prior proprietary DNA were to the much virus that last LinearDNA Takis's the Takis anti-cancer Initial causes develop compelling. for potential. in vaccines vaccine it fall for delivered vaccines to tumor and anti-cancer pre-clinical carrying based that have If holds test articulated same DNA the from sequences technology. were jointly We animal
designed constructs contain plasmids synthetic refrigeration. be scale case, manufactured target those created determined without they most RNA stable the of that are are DNA just in genomics can very unlike five of the to our or chains vaccines to COVID-XX quickly. vaccines, Takis's their that spike for antigenic. can DNA But In we LinearDNA more made also interest. be develop for that diagnostic, through engineered and need approaches and candidates vaccines the and Now, than are segments protein most easily most protein. use protein, that to more moved small of made design use be the vaccines Unlike a supply vaccine DNA the spike
bioreactor. of The patient's to the time without DNA into spike of which recognize is being a to enabling translated two provoke resides for in destroyed is immune memory immune that cells, into is the the a DNA patient for the in nucleus housekeeping for brief the nucleus the and DNA genome antibodies enzymes vaccines the by is the and and immunity use period the in design proteins and transcribed integrated immune the as convey response, just DNA cells place weeks. as expressed to the The virus about patient. After foreign.
template were vaccine from results the DNA vaccine test immunogenic show of Preliminary that across all the production antibodies strong five induce candidates. based plasmid and they they
prior anti-cancer between be results, close linear manufacture. But plasmid expect Now vaccines. correlation the in efficacy our a risks, based plasmid believe based on safety to DNA our without we LinearDNA for we and the templates issues
Takis. an DNA vaccine quarter, animals. constructs the the results the results close plasmid five and reported began the animal the versions to in neutralizing over with animals LinearDNA our few see we Last be that first produce of in a vaccine the XXst Takis next Takis expect candidates plasmid last week, to neutralizing Subsequent had model. COVID-XX we Using baseline, produced to test as its shipped of Takis to of March week, antibodies vaccine also months. dose linear antibodies the the versions candidates to test believes this to
fermentation. some plasmid if ask several the often Well, advantages, made more work, which imperative vaccine? of people a linear genome approach lower Functionally, point, antibiotic are not this gives risk for there constructs does in been to require need all DNA of of this is bacterial why advantage linear integration. At the us there potentially have This our pandemic and resistance current unwanted state.
LinearDNA plasmids, sequences. with therapeutic or contains only Unlike DNA desired the antibiotic DNA resistance no sequence bacterial
today. have global greater also manufacturer and for take speed scalability Speed scalability the importance on a and We use. advantage of to
produce vaccines. allowing distribution as are at in compared much easier with vaccines, based effective based of stable general, LinearDNA wide addition, more a as to In DNA cost variety for to vaccines RNA a more temperatures,
COVID-XX a emerges a if More diagnostic, sequenced from shown the is But variant. is design isolated which already stable by single evolve. capacity in use to X,XXX this variant that a to to large new database Finally, have humans our we what every sensitive a sensitive antibodies than vaccine. happens specific virus has been to not variants that evoked
Our DNA platform to target would technological quickly allow respond variant. linear using new us to the
we to volumes companies and design for we many trials. To-date, Research Organization Contract the pre-clinical function CRO where LinearDNA construct the or sufficient as produce
a to where therapy developers clinical and development would drug and necessary begin we relationship Contract however, scale LinearDNA to scenario, human under purposes Organization, volumes relevant consumption, therapy ability scale. customers' and the with to trial in case our for potentially our Manufacturing Takis of manufacturers best is pre-commercialization. our human Similarly, clinical becomes to DNA CMO, function a larger vaccine should be As our LinearDNA global vaccine at approved matures, for trial progressed manufacture a the a joint and as we that on
to revenue foundational commercialization is CMO to CRO a recurring to more biopharma strategy, from path and and greater our streams. Transitioning offers
them DNA use drug developer gets based clinical also drug If DNA risk a areas can faster it based can. any plasmid make therapeutic drug potentially other at with one developers that than of global purity we that other oncology, as for agnostic. lower a other approval Our platform using higher a to to is humans for and manufacturing profile again in for much developers first the such based
customer XXst the our to added base. I'd During two. we leaders quarter, several development market like March highlight to
to subsidiary the versions based biopharmaceutical focused them company is on sent therapies. They biologic we that LinearDNA based capabilities. back U.S. sent singularly first amplicons their CAR-T and is our proprietary which The global evaluate us platform’s with DNA two of a of
all interest This LifeSensors' but its or of therapies its SUMO-fusion for customer not strategy as component full therapy a rather opted our of order, treatment for in protein with own instead a is moving a of our its the platform, technologies us agreement anti-CDXX scope rather improvement our of and second them therapies that LinearDNA expression. of development gives manufacturing research lymphocytic the The construct by a differentiated specific collaboration maximize forward. platform, to for to giving customer, acute capabilities, process CAR-T for than our the CAR our leukemia access
novel in our commercialization last segment. accepted pharmaceutical increasingly technology service regulated early the ours. that security body us run and ETP has serves years, regulatory opportunity identify several pathways regulatory vertical supply manufacturing, of creates platform technology adoption product technology were the program into and tag implementation that last promote to pharmaceutical markets, pathway like a to the potential drug The development packaging. Now, and design chain and and over development a to and resolve And approaches key pharmaceuticals discuss, such by our as oversees we their DNA to through business emerging highly month, companies the and for offers help FDA's FDA’s the innovative of the technical in customers of the
Our expect to transformation manufacturers of opioid the on help we the intact. for positive inclusion whose of want path should who origin. patients The the order their chains. to point ensure seek us we hard our authenticity believe are in to ETP imagine for their is smoother pharmaceutical supply regulatory recruit or of have platform crisis employ supply in their in to drugs global pharmaceutical customers make still the DNA in might we impact their come a It not interest forensically prove the tagging to products will FDA chains of to or the marking
the hand, mitigate in more of infection fiscal our COVID-XX commercializing second diagnostic we which opportunity. help biopharma now relative our all we're believe advantages our So strongly in we're developments the With market our broadly can and our primarily of focused looking year, ahead its rates. in given to conclusion, focused kit, on us EUA half on
vaccines especially LinearDNA, We to with will Takis, therapy business. CAR-T our our our applications promising CRO stay our and the therapeutic course CMO of of
application We're can paycheck stated, very Beth near-term also full program, can as under concludes to to vital time the thank for Well, a funds receive Now the position our open we cushion to you your and pursue afternoon. Operator, remarks. DNA personnel. the which of continue my you pursue please attention to Applied our prepared so with this work call This grateful with objectives. protection cash us questions? gives our
